Sugi Predict

Sugi Predict / Compounds / SCHEMBL12221272

SCHEMBL12221272

SCHEMBL12221272

CCOC(=O)c1cn(C)nc1N(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TP53 P04637 2/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.45
▸ ADORA2A P29274 1/20 0.45
▸ ADORA1 P30542 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ BAZ2B Q9UIF8 1/20 0.43
▸ BAZ2A Q9UIF9 1/20 0.43
▸ JMJD6 Q6NYC1 1/20 0.42
▸ HSD17B10 Q99714 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CDC7 O00311 1/20 0.40
▸ DBF4 Q9UBU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267578 0.80 TSHR (0.50) ALDH1A1RAB9ANPC1TP53ADORA3
SCHEMBL4698208 0.80 TSHR (0.50) ALDH1A1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL31053360 0.79 TSHR (0.46) ALDH1A1RAB9ANPC1TP53NPSR1
SCHEMBL4296825 0.79 NPSR1 (0.61) ALDH1A1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL16760289 0.79 CRHBP (0.40) ALDH1A1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL1459312 0.78 ADORA2A (0.55) ALDH1A1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL21570104 0.78 ALDH1A1 (0.37) ALDH1A1RAB9ASMN1; SMN2ALOX15NPSR1
SCHEMBL645045 0.77 ADORA3 (0.54) ALDH1A1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL12491190 0.77 TSHR (0.47) ALDH1A1RAB9ANPC1TP53ADORA3
SCHEMBL8784632 0.77 NPC1 (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 — — EP disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 — — CN disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
CN-112118845-B MCL-1 inhibitors 吉利德科学公司 2023-06-13 — — CN disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-20220340535-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2022-10-27 — — US disclosed
EP-3793565-A1 MCL-1 INHIBITORS Gilead Sciences, Inc. (US) 2021-03-24 — — EP disclosed
CN-112118845-A MCL-1 inhibitors 吉利德科学公司 2020-12-22 — — CN disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 — — US disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 — — US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 — — US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 — — US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 — — US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 — — US disclosed
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 — — US disclosed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352271-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885
US-20200331870-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM2, GRM1 ALDH1A1 3207/4885RAB9A 2177/4885NPC1 1128/4885
US-10703733-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885
US-11643400-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885
US-20220340535-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 ALDH1A1 1991/4885RAB9A 3188/4885NPC1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback